Search Results
Your search for ASCO matches 20849 pages
Showing 3151 - 3200Dong Quai
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, focus on the herb dong...
The Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine Appoints New Directors
Jedd Wolchok, MD, PhD, FASCO, an internationally acclaimed medical oncologist whose innovations in immunotherapy have revolutionized melanoma treatment, has been chosen as the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. Dr. Wolchok played a pivotal role...
An Oncologist and His Patient With Cancer Look at the Intimate Experience of Life and Death
"This e-mail is different from my usual. No smiley faces or funny cartoons, for I have moved on to another location…. My place in the long line of life has suddenly been jumped up to the head of the queue, and now I have a boarding pass,” notes Harry, a patient with end-stage lung cancer who has...
FDA Approves Ibrutinib for Pediatric Patients With Chronic Graft-vs-Host Disease
On August 24, the U.S. Food and Drug Administration (FDA) approved ibrutinib (Imbruvica) for pediatric patients aged at least 1 year with chronic graft-vs-host disease after failure of one or more lines of systemic therapy. Formulations include capsules, tablets, and oral suspension. iMAGINE Trial...
Long-Term Benefit of Radiotherapy Confirmed in Advanced Prostate Cancer: STAMPEDE Trial Follow-up
Radiotherapy to the prostate in addition to standard treatment may improve survival for some men with advanced prostate cancer without detriment to quality of life, long-term study results from the STAMPEDE trial confirmed. These findings were published by Chris C. Parker, MD, and colleagues in...
How Did the First Year of the COVID-19 Pandemic Affect Cancer Survivors?
Recent research published by Xuesong Han, PhD, and colleagues in the journal Cancer indicated that during the first year of the COVID-19 pandemic, the proportion of working-aged U.S. adults without health insurance did not change despite increases in unemployment. The prevalence of unhealthy...
Anna Sureda, MD, PhD, on Large B-Cell Lymphoma: New Data on Axicabtagene Ciloleucel vs Standard of Care
Anna Sureda, MD, PhD, of the University of Barcelona and the Catalan Institute of Oncology, discusses phase III clinical and patient-reported outcomes from the ZUMA-7 trial, which showed that axicabtagene ciloleucel was superior to second-line standard-of-care treatment in patients 65 years or...
Harry P. Erba, MD, PhD, on AML: New Data on Quizartinib Plus Standard Chemotherapy
Harry P. Erba, MD, PhD, of Duke Cancer Institute, discusses potentially practice-changing phase III results from the QuANTUM-First trial, which showed that adding quizartinib to standard chemotherapy and up to 3 years of continuation therapy led to improvement in overall survival for adults aged 18 ...
Study Examines Effects of Advance Care Planning for Adolescents With Cancer
In a recently published study by Needle et al in JAMA Network Open, University of Minnesota researchers and colleagues say adolescents with cancer deserve a voice in medical decisions made for and about them. “Adolescents with cancer should be given the opportunity to participate in their own...
Proximity to Fracking Sites May Be Associated With Risk of Pediatric Leukemia
Children in Pennsylvania living near unconventional oil and gas developments at birth were two to three times more likely to be diagnosed with leukemia between the ages of 2 and 7 years than children who did not live near this oil and gas activity, after accounting for other factors that could...
Cancer-Related Fatigue Linked to Balance Problems After Chemotherapy for Breast Cancer
For many patients who have received chemotherapy for breast cancer, cancer-related fatigue is a persistent side effect—and one that contributes to ongoing balance problems, suggests a recent paper published by Weschler et al in Rehabilitation Oncology. The new research by Stephen Wechsler, PT, DPT, ...
Nine Oncology Practices Certified Through ASCO Patient-Centered Cancer Care Certification Pilot
ASCO recently announced that nine outpatient oncology group practices have achieved certification through the new ASCO Patient-Centered Cancer Care Certification pilot based on their adherence to oncology medical home (OMH) standards, a single set of comprehensive, expert-backed standards for...
2023 Hospital Outpatient Payment Proposal Does Not Reflect SCOTUS Ruling on 340B Reimbursement
On July 15, 2022, the Centers for Medicare & Medicaid Services (CMS) released its proposed rule for the 2023 Medicare Hospital Outpatient Prospective Payment System (OPPS). ASCO is assessing the full proposal, but ASCO’s initial analysis is as follows. In June 2022, the Supreme Court ruled that ...
New Guideline Updates Address Stage IV Non–Small Cell Lung Cancer With and Without Driver Alterations
Two ASCO guideline updates provide new evidence-based recommendations for the systemic treatment of stage IV non–small cell lung cancer (NSCLC) with and without driver alterations.1,2 Among several other updates, these new guidelines add the ALK and ROS1 inhibitor lorlatinib and the PD-L1 immune...
Biden Administration Announces New Model to Improve Cancer Care for Medicare Patients
On June 27, 2022, the Biden Administration, through the U.S. Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS), announced a new model aimed at improving cancer care for Medicare patients and lowering health-care costs. CMS’ Center for Medicare...
Anthony S. Fauci, MD, to Step Down From Current Roles in December
Anthony S. Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases (NIAID), announced his intention to step down from his various roles in December 2022. He issued the following statement on August 22: I am announcing today that I will be stepping down from the positions...
Racial Trends in Advanced Cervical Cancer in the United States
The steepest annual rise in new cases of advanced cervical cancer in the United States from 2001 to 2018 was among White patients, who were significantly less likely to receive the preventive human papillomavirus (HPV) vaccine or to be screened for the disease, according to research published by...
Study Evaluates UV Protective Behaviors in American Indian and Alaskan Native Populations
Ultraviolet (UV) protection from the sun and avoiding indoor tanning play important roles in reducing a person’s risk for skin cancer, the most common cancer in the United States and one of the most preventable. A recent article published by Yang et al in the Journal of the American Academy of...
Expert Point of View: Katrina S. Pedersen, MD, MS
Katrina S. Pedersen, MD, MS, Assistant Professor of Medicine at Washington University School of Medicine, St. Louis, said while the results of the phase II -SEQUENCE trial1 are encouraging and the drugs are available to translate into the clinic without delay, phase III validation would be needed...
Sequencing Therapies May Improve Overall Survival in Metastatic Pancreatic Cancer
In the first-line treatment of metastatic pancreatic cancer, the sequencing of nab-paclitaxel plus gemcitabine with FOLFOX (fluorouracil, leucovorin, oxaliplatin) resulted in a significant improvement in overall survival at 12 months and in all other efficacy endpoints as compared with the standard ...
Snapshots of Studies of Interest Presented at ASCO 2022
The 2022 ASCO Annual Meeting was filled with important science, engaging data, and several practice-changing abstracts, many of which have been covered in detail on other pages or in earlier issues of The ASCO Post. There were numerous high-impact studies and attendees, whether present at the...
Impact of the Dobbs v Jackson Women’s Health Organization Ruling on Patients With Cancer
As a nonpartisan organization, the American Cancer Society has an overarching goal to improve the lives of patients with cancer and their families. We believe all individuals should have an equitable opportunity to prevent, find, detect, and survive cancer, irrespective of geography. The June 24...
Is Science Getting Closer to Preventing Multiple Myeloma?
About 3 years ago, researchers from Dana-Farber Cancer Institute launched PROMISE (Predicting Progression of Developing Myeloma in a High-Risk Screen Population; ClinicalTrials.gov identifier NCT03689595), a large, ambitious screening study to identify individuals at high risk of developing...
ASCO 2022: Conversations in Colorectal Cancer
On this episode, we’re featuring discussions about data in colorectal cancer that were presented at the 2022 ASCO Annual Meeting. Dr. Michael Overman, of The University of Texas MD Anderson Cancer Center, speaks with two presenters about guiding therapy with circulating tumor DNA and refining...
Expert Point of View: Alexey V. Danilov, MD, PhD
According to Alexey V. Danilov, MD, PhD, Professor and Co-Director, Toni Stephenson Lymphoma Center, City of Hope, diffuse large B-cell lymphoma (DLBCL) refractory to chemotherapy represents an unmet medical need, with data from the SCHOLAR-1 study demonstrating a median overall survival of...
PREMMplus Tool May Assist in Identifying People Likely to Benefit From Multigene Hereditary Cancer Risk Assessment
An online tool developed by researchers and physicians at Dana-Farber Cancer Institute may accurately and rapidly identify people who should undergo testing for inherited genetic changes that raise the risk of developing certain cancers, according to findings reported by Yurgelun et al in the...
Study Tests Strategy for Reducing Colorectal Cancer Risk Among Patients With Familial Adenomatous Polyposis
Researchers from the Mayo Clinic Comprehensive Cancer Center and the Mayo Clinic Center for Individualized Medicine are studying the rare genetic condition called familial adenomatous polyposis, looking for potential ways to prevent colorectal cancer in the general population at an earlier, more...
Is Advance Care Planning of Any Value?
An article in The New York Times earlier this year crystallized the dilemma facing health-care providers when they are presented with a patient in a life-threatening situation: Should they rely on advance care directives written years prior to the current medical situation to accurately determine...
Does Exposure to 'Forever Chemical' Elevate Risk of Developing Hepatocellular Carcinoma?
Exposure to a synthetic chemical found widely in the environment may be linked to the development of nonviral hepatocellular carcinoma, according to a new study published by Goodrich et al in JHEP Reports. The chemical—called perfluorooctane sulfate, or PFOS—is one of a class of man-made chemicals...
T-DXd Shows High Intracranial Response Rate in Patients With Active Brain Metastases From HER2-Positive Breast Cancer
In the investigator-initiated, prospective, open-label, single-arm phase II TUXEDO-1 study conducted among patients with newly diagnosed or progressive brain metastases from HER2-positive breast cancer, the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) yielded responses according...
Expert Point of View: Michael Cecchini, MD
The ASCO Post asked Michael Cecchini, MD, Assistant Professor of Medicine and Co-Director of the Colorectal Program in the Center for Gastrointestinal Cancer at Yale School of Medicine and Smilow Cancer Hospital Center, New Haven, to comment on the RATIONALE-306 findings. He said the study...
Study Shows Germline Testing May Be Warranted for All Patients With Lung Cancer
Germline testing may be warranted for all patients with lung cancer, according to research presented by Sorscher et al during the August ASCO Plenary Series Program (Abstract 388570). The retrospective review of nearly 8,000 patients with lung cancer undergoing germline testing found that 14.9% had ...
FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients With Beta-Thalassemia Who Require Regular Blood Transfusions
On August 17, the U.S. Food and Drug Administration (FDA) approved betibeglogene autotemcel (Zynteglo), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. “[This] approval is an important...
Pralsetinib Achieves Tissue-Agnostic Benefits for Patients With RET Fusion–Positive Cancers
The highly selective RET inhibitor pralsetinib was well tolerated and demonstrated robust, durable responses in patients with RET fusion–positive cancers regardless of tumor type, according to results from the international phase I/II ARROW trial. Results from the trial were published in Nature...
Study Reveals Potential Genomic Contributors to the Development of DLBCL
By searching previously ignored regions of the genome, researchers have found a multitude of new genetic mutations that may contribute to diffuse large B-cell lymphoma (DLBCL). These findings were published by Bal et al in Nature. “Our findings not only show that these mutations can contribute to...
A Surgical Oncologist From Afghanistan Discusses the Challenges of Delivering Cancer Care in a War-Torn Nation
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Ahmad Bashir Barekzai, MD, FACS, Consultant Surgical Oncologist at Ali Abad Teaching Hospital, an affiliated hospital to Kabul University of Medical Science, Kabul,...
Relationship Between Polypharmacy and Frailty Among Older Adults With Blood Cancers
A new study published by Hshieh et al in JNCCN–Journal of the National Comprehensive Cancer Network suggests a new way for hematologic oncologists to protect older patients from the risks of medication interactions. As part of the Older Adult Hematologic Malignancies Program, gerontology...
Molecular Map Reveals Insights Into the Genetic Drivers of CLL
A newly constructed map of the landscape of genetic changes in chronic lymphocytic leukemia (CLL) may provide a better understanding of this complex malignancy, which could lead to more accurate prognoses for patients, improved diagnostics, and novel treatments. These research findings were...
Sugemalimab Found to Be a Safe and Effective Consolidation Therapy for Patients With Unresectable Stage III NSCLC
The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non–small cell lung cancer (NSCLC) without disease progression after either concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy (sCRT), according to...
Higher Doses of CAR T-Cell Therapy May Improve Survival for Young Patients With B-Cell ALL
Young people with B-cell acute lymphoblastic leukemia (ALL) who received doses of tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy, at the higher end of the approved dosing range had significantly better survival rates at 1 year compared with those who received lower doses within...
Sexual Dysfunction Is Prevalent Among Women With Lung Cancer
Sexual dysfunction is highly prevalent in women with lung cancer, with most participants in a survey reporting little to no interest in sexual activity, according to research led by Narjust Florez (Duma), MD, presented at the International Association for the Study of Lung Cancer (IASLC) World...
Study Investigates Incidence, Timing, and Survival of Patients With Second Primary Lung Cancer
Using data from the National Lung Screening Trial (NLST), researchers found that the incidence of second primary lung cancer was approximately 4% among the entire cohort of patients with lung cancer and was as high as 8% among patients undergoing surgery for stage IA disease. The research was...
NELSON Trial Protocol May Be More Sensitive Than NLST, May Increase Benefits of Lung Cancer Screening
The protocol used to screen and detect lung cancer in the NELSON trial may be more sensitive than the protocol used in the National Lung Cancer Screening Trial (NLST), particularly for early-stage cancers, according to research reported by de Nijs et al at the International Association for the...
Perspective Article Explores Implications of Supreme Court Abortion Ruling on Pregnant Women With Cancer
The repercussions of overturning Roe v Wade—and the failure of the Supreme Court to provide any guidance on exceptions related to the life and health of the mother—are potentially catastrophic for a subset of women who face a life-threating diagnosis of pregnancy-associated cancers. In a...
ASCO 2022: Conversations in Leukemia
Dr. Courtney DiNardo, of The University of Texas MD Anderson Cancer Center, sat down with two colleagues at the 2022 ASCO Annual Meeting to discuss data presented in leukemia. On this episode of the podcast, we’re featuring Dr. DiNardo’s conversations.
Informed Consent Forms for Lung Cancer Clinical Trials May Be a Barrier to Informed Participation
Informed consent forms can be overwhelming for patients—they are written at a level that is too high for many patients, possibly impeding true informed consent, according to a report given by King-Kallimanis et al at the International Association for the Study of Lung Cancer (IASLC) 2022 World...
Durvalumab Plus Concurrent Radiotherapy in Unresectable Locally Advanced NSCLC: DOLPHIN Study
Researchers from Japan recently reported that the first phase II study to evaluate the efficacy and safety of durvalumab and concurrent curative radiation therapy for PD-L1–positive unresectable locally advanced non–small cell lung cancer (NSCLC) without chemotherapy met its primary endpoint with...
FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for HER2-Mutant NSCLC
On August 11, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for adult patients with unresectable or metastatic non–small cell lung cancer (NSCLC) whose tumors have activating HER2 mutations, as detected by an...
FDA Approves Capmatinib for Metastatic NSCLC With MET Exon 14 Skipping Mutations
On August 10, 2022, the U.S. Food and Drug Administration (FDA) granted regular approval to capmatinib (Tabrecta) for adult patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an ...
Research Suggests Air Pollution Be Included as Risk Factor for Nonsmoking Patients With Lung Cancer
Researchers from Vancouver, British Columbia examined the effect of duration of past exposure to air pollution with lung cancer diagnosis in new research presented by Myers et al at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2022 (Abstract...
